TickerTalks
Browse all tickers →
TickerTalks›$THC
THTHC

Tenet Healthcare Corporation

$THC·$21B·Medical - Care Facilities·Healthcare
$263.69+0.1%YTD+32.6%1Y+36.4%
Price updated 13h ago·X counts updated 2d ago
THTHC
$THCTenet Healthcare Corporation
$263.69+0.09%364 posts1.2×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $THC on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

364X posts · last 7 days
Aug 28Sep 10
Chatter Meter
1.2×
QuietNormal · 1×Loud

How loud $THC's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 63% of tracked names.

Neutral sentimentAI analysisGenerated by AI from underlying data23 posts analyzed · as of 2026-09-11

The $THC cashtag is the Tin Hat Cat memecoin migrating from Sonic to the Robinhood chain — community lore, launch anticipation, cat SZN framing — not Tenet Healthcare the equity. This window carries no stock signal.

Read what X is saying about $THC

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $THC — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersCooling offAI verdict · as of 2026-09-11

Catching its breath after a run — could pick back up or fade from here.

Investor-owned hospital operator up 37% in twelve months — with the CEO cashing out $28M and the debt structure just refinanced upward.

Tenet Healthcare runs a network of hospitals and ambulatory surgery centers, and it's been one of the quiet outperformers in healthcare — up 37% over twelve months on structural improvement in the outpatient-services mix. The stock now trades at 84% of its 52-week range with real insider distribution.

  • The economics are actually strong: 10x TTM earnings for a business earning 51% ROE and 17% operating margins, plus a 13.6% free-cash-flow yield — a legitimately cheap large-cap that's compounding earnings 15%+ annually on the outpatient-shift thesis. Q1 revenue grew 6.8% year-over-year, and USPI (surgery-center) is doing the operating lift.
  • The balance sheet just got restructured: Tenet upsized and priced a $2B senior notes offering to refinance $1.5B in outstanding notes — pushes maturities out, keeps leverage manageable at 2.8x debt-to-equity, and validates that credit markets like the story. That's proactive liability management, not defensive.
  • The insider read is loud and negative: CEO Saumya Sutaria sold $27.6M across two filings plus CIO Lisa Foo sold $6.4M — meaningful post-run distribution from senior operators. This isn't a thesis change, but it is the ceiling on how much the stock runs from here without new demand absorbing the supply.

The bet is whether Q3 on Oct 27 confirms the USPI outpatient-mix expansion is sustainable — the number to watch is USPI same-facility revenue growth above 8%. A clean print re-rates this toward $290; another in-line quarter combined with continued CEO selling caps the upside at the recent range.

What to watch: Oct 27 Q3 earnings — specifically USPI same-facility revenue growth above 8% and any 2027 outpatient-mix framing. Clean print re-rates toward $290; in-line combined with continued CEO selling caps the upside near the recent highs.

On the calendar: 2026-10-27 — Q3 earnings

Read the AI verdict on $THC

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Hospital and ambulatory surgery center operator with 65+ acute care hospitals and 500+ outpatient centers across the US.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Care Facilities sits in its cycle right now — and what that implies for $THC.

Medical - Care Facilities · Healthcare

Hospital and care-facility volumes have normalised with payer-mix shift back toward commercially insured; AI-administrative tools are improving hospital operating efficiency. Medicaid redetermination headwinds and labour-cost pressure are the key risks.

What this means for $THC

Direct beneficiary — Tenet Healthcare; hospital volumes and payer-mix improving, Usph ambulatory surgery centres growing.

Top industry ETF

$IHFiShares U.S. Healthcare Providers ETF
+17.9%YTD
+15.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
9.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
11.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
16.8%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
13.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
50.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
26.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
2.8Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 23, 2026$6.12$4.26+43.7%
Q1 2026Apr 30, 2026$4.82$4.17+15.6%
Q4 2025Feb 11, 2026$4.70$4.07+15.5%
Q3 2025Oct 28, 2025$3.70$3.34+10.8%
Next earningsTue, Oct 27·consensus EPS $4.67

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$5.6B+6.8%18.2%18.2%$9.89$417.0M
Q1 FY26$5.4B+2.8%16.4%16.4%$8.09$1.5B
Q4 FY25$5.5B+9.0%15.7%15.7%$4.25$367.0M
Q3 FY25$5.3B+3.3%58.3%16.8%$3.89$778.0M

Forward consensus

4-year forecast · up to 15 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$22.2B$22.2B – $22.3B$21.22$20.49 – $21.7315
FY27$22.5B$22.3B – $23.1B$21.08$19.14 – $23.4915
FY28$23.6B$23.0B – $24.5B$23.00$19.85 – $26.3514
FY29$24.1B$23.7B – $25.1B$28.72$28.08 – $30.328

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.85%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+8.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+25.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 79.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.235-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 2Nadja WestDirector1.2K sh$298KSellAug 31Lisa Y FooCOO24.0K sh$6.4MSellAug 25Saumya SutariaCEO50.0K sh$13.7MSellAug 24Cecil D HaneyDirector1.3K sh$361KSellAug 24Saumya SutariaCEO50.0K sh$13.9MSellAug 7Tammy RomoDirector2.5K sh$652KSellAug 6Tammy RomoDirector4.9K sh$1.3MSellAug 5Roy BluntDirector600 sh$158KSellJul 29Lisa Y FooCOO10.0K sh$2.6MSellJul 27Christopher S. LynchDirector3.8K sh$934K
1–10 of 14
+ 31 other (11 awards · 11 exempts · 8 returns · 1 gift) in window

See when $THC insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDSep 88-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Tenet Healthcare Corporation announced the commencement of a $1.5 billion private placement of senior notes due 2034 under Rule 144A/Reg S for institutional investors, with a subsequent registered exchange offer to follow. Proceeds are expected to fund debt refinancing or general corporate purposes at the large for-profit hospital operator. This substantial high-yield debt raise reflects Tenet's continued management of its leveraged capital structure.

8-KShareholder voteMay 298-K — Item 5.07: Shareholder vote
3New insider — initial holdingsMay 83
8-KOfficer or director changeApr 108-K — Item 5.02: Officer or director change
8-KOfficer or director changeMar 308-K — Item 5.02: Officer or director change
+ 12 other (5 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Why Tenet Healthcare (THC) is a Top Growth Stock for the Long-Termzacks.com·1d agoTenet Healthcare Corporation (THC) Presents at Wells Fargo 21st Annual Healthcare Conference Transcriptseekingalpha.com·3d agoTenet Announces Upsizing and Pricing of Its $2.0 Billion Private Offering of Senior Notesbusinesswire.com·4d agoTenet Announces Private Offering of Senior Notes to Refinance $1.5 Billion in Outstanding Notesbusinesswire.com·4d agoNew Strong Buy Stocks for September 8thzacks.com·4d ago

More in Medical - Care Facilities

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$HIMS$STLN$AVAH$NUTX$CON$NHC$ASTH$PNTG
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport